Apogee Therapeutics (APGE) Stifel 2024 Healthcare Conference summary

Strategic focus and market overview

• Targeting large, underpenetrated I&I markets such as atopic dermatitis, asthma, and COPD with differentiated antibodies and known biology for improved dosing and efficacy.

• R&D day scheduled for December 2 will provide pipeline updates, combination strategies, and commercial plans, featuring KOLs.

• Commercial research indicates strong patient and physician preference for less frequent dosing if efficacy and safety match current standards.

• Early market data from Europe shows rapid uptake of new therapies, with expectations for continued growth and increased biologic penetration.

• Cash runway extends into 2028, supporting advancement of multiple programs and future financing flexibility.

Pipeline and clinical development updates

• APG777, the lead program, targets IL-13 with an optimized IgG1 backbone, offering higher concentration and manufacturability benefits.

• Phase I data for APG777 showed a 75-day half-life and strong biomarker responses, with phase II readout expected in the second half of 2025.

• APG808, targeting IL-4 receptor alpha, aims for a 40-day half-life to enable 6-8 week dosing; phase I data expected before year-end.

• APG990 (OX40L) and APG333 (TSLP) are positioned as combination partners to enhance efficacy, with phase I and preclinical data forthcoming.

• Combination studies, including APG777 and APG990, are planned for 2025, with further details to be shared at the upcoming R&D day.

Commercial and financial strategy

• Market research shows high willingness among patients and physicians to adopt therapies with less frequent dosing.

• Payers are expected to grant first-line access if efficacy and safety are comparable to current standards.

• Expansion into asthma and other indications is planned, leveraging overlap in patient populations and strong biological rationale.

• Structured financings, such as royalty deals, are under consideration to support future growth.

• Phase II data in atopic dermatitis is seen as a major de-risking event, with high correlation to phase III outcomes.